News

(RTTNews) - Oncology firm Immuneering Corp. (IMRX) Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for its lead clinical-stage program IMM-1-104, for the treatment of patients with pancreatic ductal adenocarcinoma, who have failed one line of treatment.

In the pre-market session, shares are up 4.85 percent from the previous close of $6.60 on a volume of 22,417.

The Fast Track Designation will help accelerate approval and priority review of the drug candidate.

IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing.

In its Phase 1/2a study, the company plans to evaluate IMM-1-104 in pancreatic cancer and other tumor types.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.